Amie L. Hiller
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Amie L. Hiller has a total of 129 co-authors. Here are the top co-authors by number of shared publications:
- Deepak Kumar Gupta
Office of Medical Student Education, Robert Larner College of Medicine, University of Vermont, Burlington, VT, USA
5 shared publications - Cyrus P. Zabetian
Veterans Affairs Puget Sound Health Care System, Seattle, WA, USA
4 shared publications - Cole Zweber
Office of Medical Student Education, Robert Larner College of Medicine, University of Vermont, Burlington, VT, USA
3 shared publications - Curtis Tatsuoka
University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania
3 shared publications Dakota Clarke
Parkinsons Disease Research, Education, and Clinical Center (PADRECC), Department of Neurology, VA Portland Health Care System, Portland, USA; Department of Neurology, Oregon Health & Sciences University, Portland, USA
3 shared publicationsIan Zurlo
Department of Neurology, University of Vermont Medical Center, Burlington, USA
3 shared publications
Latest Publications
- Open Access
- 16 October 2026
- Published by Springer Nature in Scientific Reports
Modeling the heterogeneity of cognitive dysfunction in Parkinson’s disease using partially ordered set models
Traditional binary classifications of Parkinson’s disease (PD) cognitive dysfunction fail to capture its inherent heterogeneity. This study introduces the Partially Ordered Set (POSET) model, a Bayesian framework, to analyze cognitive heterogeneity using Parkinson’s Precision Medicine Initiative (PPMI) data. Five cognitive domains: Attention, Visuospatial Judgement, Executive Functioning, Working Memory, and Episodic Memory, were mapped onto nine neuropsychological measures to calculate Cognitive Performance Scores (CPS). Of 264 participants without baseline cognitive dysfunction, 21.2% developed dysfunction by Year 3. After demographic adjustment and Bonferroni correction, cognitive dysfunction at Year 3 was inversely associated with median CPS values for: Attention (across all visits); Executive Functioning and Working Memory (Year 1 onward); and Visuospatial Judgement (baseline only). In multivariable logistic regression, both baseline Attention and Visuospatial Judgement CPS were significant predictors of future impairment without adjustment for baseline disease duration, however, only Visuospatial Judgement CPS remained a significant predictor after the adjustment. POSET modeling provides a sophisticated approach to characterizing PD cognitive decline, offering greater granularity than conventional schemes. Further large-cohort studies are needed to confirm these findings.
- 16 October 2026
- Published by Springer Nature in Scientific Reports
Open AccessModeling the heterogeneity of cognitive dysfunction in Parkinson’s disease using partially ordered set models
Traditional binary classifications of Parkinson’s disease (PD) cognitive dysfunction fail to capture its inherent heterogeneity. This study introduces the Partially Ordered Set (POSET) model, a Bayesian framework, to analyze cognitive heterogeneity using Parkinson’s Precision Medicine Initiative (PPMI) data. Five cognitive domains: Attention, Visuospatial Judgement, Executive Functioning, Working Memory, and Episodic Memory, were mapped onto nine neuropsychological measures to calculate Cognitive Performance Scores (CPS). Of 264 participants without baseline cognitive dysfunction, 21.2% developed dysfunction by Year 3. After demographic adjustment and Bonferroni correction, cognitive dysfunction at Year 3 was inversely associated with median CPS values for: Attention (across all visits); Executive Functioning and Working Memory (Year 1 onward); and Visuospatial Judgement (baseline only). In multivariable logistic regression, both baseline Attention and Visuospatial Judgement CPS were significant predictors of future impairment without adjustment for baseline disease duration, however, only Visuospatial Judgement CPS remained a significant predictor after the adjustment. POSET modeling provides a sophisticated approach to characterizing PD cognitive decline, offering greater granularity than conventional schemes. Further large-cohort studies are needed to confirm these findings.
- Open Access
- 9 July 2026
- Published by Ubiquity Press, Ltd. in Tremor and Other Hyperkinetic Movements
- Vol. 16 (1) , 44
Correction: A Case of Cala Trio-Induced Glossopharyngeal Neuralgia in a Patient with Essential Tremor and Idiopathic Parkinson’s Disease
This article details a correction to Arnold, M.R. and Hiller, A.L. (2026) ‘A Case of Cala Trio-Induced Glossopharyngeal Neuralgia in a Patient with Essential Tremor and Idiopathic Parkinson’s Disease’, Tremor and Other Hyperkinetic Movements, 16(1), p. 41. Available at: https://doi.org/10.5334/tohm.1224.
- 9 July 2026
- Published by Ubiquity Press, Ltd. in Tremor and Other Hyperkinetic Movements
- Vol. 16 (1) , 44
Open AccessCorrection: A Case of Cala Trio-Induced Glossopharyngeal Neuralgia in a Patient with Essential Tremor and Idiopathic Parkinson’s Disease
This article details a correction to Arnold, M.R. and Hiller, A.L. (2026) ‘A Case of Cala Trio-Induced Glossopharyngeal Neuralgia in a Patient with Essential Tremor and Idiopathic Parkinson’s Disease’, Tremor and Other Hyperkinetic Movements, 16(1), p. 41. Available at: https://doi.org/10.5334/tohm.1224.
- Open Access
- 15 June 2026
- Published by Ubiquity Press, Ltd. in Tremor and Other Hyperkinetic Movements
- Vol. 16 (1) , 41
A Case of Cala Trio-Induced Glossopharyngeal Neuralgia in a Patient with Essential Tremor and Idiopathic Parkinson’s Disease
Background: Cala Trio is a wrist-worn transcutaneous afferent patterned stimulation (TAPS) device for essential tremor (ET), delivering high-frequency stimulation to the median and radial nerves. Case Report: We report the first case of glossopharyngeal neuralgia (GPN) associated with Cala Trio initiation in a 69-year-old male with ET and Parkinson’s disease, with prior GPN. Throat spasms triggered by swallowing and coughing began after initiation on two trials and resolved with discontinuation; evaluation was unrevealing. Discussion: We review TAPS mechanisms, GPN neuroanatomy, and circuit-level links between peripheral nerve stimulation and brainstem cranial nerve hyperexcitability, highlighting a novel adverse event and need for caution in patients with prior GPN. Highlights We report the first case of glossopharyngeal neuralgia associated with Cala Trio TAPS therapy in a patient with essential tremor and Parkinson’s disease. Symptoms were temporally linked to device use and resolved upon discontinuation, suggesting a reversible neuromodulation-related effect and expanding the safety profile of peripheral tremor therapies.
- 15 June 2026
- Published by Ubiquity Press, Ltd. in Tremor and Other Hyperkinetic Movements
- Vol. 16 (1) , 41
Open AccessA Case of Cala Trio-Induced Glossopharyngeal Neuralgia in a Patient with Essential Tremor and Idiopathic Parkinson’s Disease
Background: Cala Trio is a wrist-worn transcutaneous afferent patterned stimulation (TAPS) device for essential tremor (ET), delivering high-frequency stimulation to the median and radial nerves. Case Report: We report the first case of glossopharyngeal neuralgia (GPN) associated with Cala Trio initiation in a 69-year-old male with ET and Parkinson’s disease, with prior GPN. Throat spasms triggered by swallowing and coughing began after initiation on two trials and resolved with discontinuation; evaluation was unrevealing. Discussion: We review TAPS mechanisms, GPN neuroanatomy, and circuit-level links between peripheral nerve stimulation and brainstem cranial nerve hyperexcitability, highlighting a novel adverse event and need for caution in patients with prior GPN. Highlights We report the first case of glossopharyngeal neuralgia associated with Cala Trio TAPS therapy in a patient with essential tremor and Parkinson’s disease. Symptoms were temporally linked to device use and resolved upon discontinuation, suggesting a reversible neuromodulation-related effect and expanding the safety profile of peripheral tremor therapies.
- 28 January 2026
- Published by Elsevier in Parkinsonism & Related Disorders
- Vol. 144, 108220
Parkinson's disease with and without history of Agent Orange exposure: A prospective study of US Veterans
- 28 January 2026
- Published by Elsevier in Parkinsonism & Related Disorders
- Vol. 144, 108220
Parkinson's disease with and without history of Agent Orange exposure: A prospective study of US Veterans
- Open Access
Parkinson’s Disease With and Without History of Agent Orange Exposure: A Prospective Study of US Veterans
Environmental neurotoxins have been implicated in the pathogenesis of Parkinsons disease (PD), with Agent Orange (AO) recognized as a presumptive service-connected exposure among U.S. Veterans. However, prospective data examining potential clinical differences associated with AO exposure remain limited. We conducted a multicenter prospective cohort study of U.S. Veterans with PD to compare demographic and clinical characteristics between individuals with and without a history of AO exposure. Clinical assessments included cognitive testing, motor and non-motor symptom scales, activities of daily living, and a global composite outcome. Among 40 Veterans analyzed, no statistically significant differences were observed between exposed and unexposed groups on univariate analyses. However, trend-level differences suggested lower cognitive performance and greater patient-reported motor disability among AO-exposed Veterans. While exploratory and limited by sample size, these findings suggest potential clinically meaningful distinctions that warrant confirmation in larger cohorts. Improved characterization of PD phenotypes associated with environmental toxin exposure may inform prognostic counselling and care of affected Veterans.
Open AccessParkinson’s Disease With and Without History of Agent Orange Exposure: A Prospective Study of US Veterans
Environmental neurotoxins have been implicated in the pathogenesis of Parkinsons disease (PD), with Agent Orange (AO) recognized as a presumptive service-connected exposure among U.S. Veterans. However, prospective data examining potential clinical differences associated with AO exposure remain limited. We conducted a multicenter prospective cohort study of U.S. Veterans with PD to compare demographic and clinical characteristics between individuals with and without a history of AO exposure. Clinical assessments included cognitive testing, motor and non-motor symptom scales, activities of daily living, and a global composite outcome. Among 40 Veterans analyzed, no statistically significant differences were observed between exposed and unexposed groups on univariate analyses. However, trend-level differences suggested lower cognitive performance and greater patient-reported motor disability among AO-exposed Veterans. While exploratory and limited by sample size, these findings suggest potential clinically meaningful distinctions that warrant confirmation in larger cohorts. Improved characterization of PD phenotypes associated with environmental toxin exposure may inform prognostic counselling and care of affected Veterans.
- Open Access
CDS-PD: A Novel Clinical Decision Support Platform for Parkinson’s Disease
Objectives The Movement Disorders Society clinical diagnostic criteria for Parkinson’s disease (MDS-PD) allow highly sensitive and specific diagnosis of Parkinson’s disease. However, their adoption has been limited due to lack of a clinical decision support (CDS) tool to support clinicians and researchers in systematically and accurately applying the MDS-PD criteria Materials and Methods We have developed and evaluated a CDS platform for PD (CDS-PD) as a modular and extensible informatics platform with comprehensive functionalities for recording relevant patient information. We have performed real time application of diagnostic algorithm of the MDS-PD criteria. Results The CDS-PD platform shows high concordance with application of the MDS-PD criteria by experienced movement disorders neurologists. Discussion The CDS-PD platform is a transformative step towards realizing the standardized electronic implementation of the MDS-PD criteria for PD patient care and clinical trials at point-of-care. Conclusion The CDS-PD platform can be accessed after registration at weblink https://www.cdspd.org LAY SUMMARY Diagnostic criteria for Parkinson’s disease (PD) have been developed to improve accuracy of clinical diagnosis of PD. However, these criteria are inherently complex to apply using a manual approach with pen-and-paper and are not supported in electronic health record systems. There is a need for a clinical decision support (CDS) system to support clinicians and researchers alike in the implementation of these criteria. We developed a novel technology platform to address this unmet need.
Open AccessCDS-PD: A Novel Clinical Decision Support Platform for Parkinson’s Disease
Objectives The Movement Disorders Society clinical diagnostic criteria for Parkinson’s disease (MDS-PD) allow highly sensitive and specific diagnosis of Parkinson’s disease. However, their adoption has been limited due to lack of a clinical decision support (CDS) tool to support clinicians and researchers in systematically and accurately applying the MDS-PD criteria Materials and Methods We have developed and evaluated a CDS platform for PD (CDS-PD) as a modular and extensible informatics platform with comprehensive functionalities for recording relevant patient information. We have performed real time application of diagnostic algorithm of the MDS-PD criteria. Results The CDS-PD platform shows high concordance with application of the MDS-PD criteria by experienced movement disorders neurologists. Discussion The CDS-PD platform is a transformative step towards realizing the standardized electronic implementation of the MDS-PD criteria for PD patient care and clinical trials at point-of-care. Conclusion The CDS-PD platform can be accessed after registration at weblink https://www.cdspd.org LAY SUMMARY Diagnostic criteria for Parkinson’s disease (PD) have been developed to improve accuracy of clinical diagnosis of PD. However, these criteria are inherently complex to apply using a manual approach with pen-and-paper and are not supported in electronic health record systems. There is a need for a clinical decision support (CDS) system to support clinicians and researchers alike in the implementation of these criteria. We developed a novel technology platform to address this unmet need.
- Open Access
Modeling the Heterogeneity and Trajectories of Cognitive Dysfunction in Parkinson’s Disease Using Partially Ordered Set Models
Traditional binary classifications of Parkinson’s disease (PD) cognitive dysfunction fail to capture its inherent heterogeneity. This study introduces the Partially Ordered Set (POSET) model, a Bayesian framework, to analyze cognitive trajectories using Parkinson’s Progression Markers Initiative (PPMI) data. Five cognitive domains: Attention, Visuospatial Judgement, Executive Functioning, Working Memory, and Episodic Memory, were mapped onto nine neuropsychological measures to calculate Cognitive Performance Scores (CPS). Of 264 patients without baseline cognitive dysfunction, 21.7% developed dysfunction by Year 3. These individuals exhibited significantly lower median CPS across all domains during follow up visits in Years 1-3. Notably, baseline Attention and Visuospatial CPS were significant predictors of future impairment, with an area under the curve (AUC) of 0.782; a specificity of 91.3%, and a sensitivity or 35.7%. POSET modeling provides a sophisticated approach to characterizing PD cognitive decline, offering greater granularity than conventional schemes. Further large-cohort studies are needed to confirm these findings.
Open AccessModeling the Heterogeneity and Trajectories of Cognitive Dysfunction in Parkinson’s Disease Using Partially Ordered Set Models
Traditional binary classifications of Parkinson’s disease (PD) cognitive dysfunction fail to capture its inherent heterogeneity. This study introduces the Partially Ordered Set (POSET) model, a Bayesian framework, to analyze cognitive trajectories using Parkinson’s Progression Markers Initiative (PPMI) data. Five cognitive domains: Attention, Visuospatial Judgement, Executive Functioning, Working Memory, and Episodic Memory, were mapped onto nine neuropsychological measures to calculate Cognitive Performance Scores (CPS). Of 264 patients without baseline cognitive dysfunction, 21.7% developed dysfunction by Year 3. These individuals exhibited significantly lower median CPS across all domains during follow up visits in Years 1-3. Notably, baseline Attention and Visuospatial CPS were significant predictors of future impairment, with an area under the curve (AUC) of 0.782; a specificity of 91.3%, and a sensitivity or 35.7%. POSET modeling provides a sophisticated approach to characterizing PD cognitive decline, offering greater granularity than conventional schemes. Further large-cohort studies are needed to confirm these findings.
- Open Access
- 22 March 2022
- Published by MDPI AG in Metabolites
- Vol. 12 (4) , 277
Predictive Modeling of Alzheimer’s and Parkinson’s Disease Using Metabolomic and Lipidomic Profiles from Cerebrospinal Fluid
In recent years, metabolomics has been used as a powerful tool to better understand the physiology of neurodegenerative diseases and identify potential biomarkers for progression. We used targeted and untargeted aqueous, and lipidomic profiles of the metabolome from human cerebrospinal fluid to build multivariate predictive models distinguishing patients with Alzheimer’s disease (AD), Parkinson’s disease (PD), and healthy age-matched controls. We emphasize several statistical challenges associated with metabolomic studies where the number of measured metabolites far exceeds sample size. We found strong separation in the metabolome between PD and controls, as well as between PD and AD, with weaker separation between AD and controls. Consistent with existing literature, we found alanine, kynurenine, tryptophan, and serine to be associated with PD classification against controls, while alanine, creatine, and long chain ceramides were associated with AD classification against controls. We conducted a univariate pathway analysis of untargeted and targeted metabolite profiles and find that vitamin E and urea cycle metabolism pathways are associated with PD, while the aspartate/asparagine and c21-steroid hormone biosynthesis pathways are associated with AD. We also found that the amount of metabolite missingness varied by phenotype, highlighting the importance of examining missing data in future metabolomic studies.
- 22 March 2022
- Published by MDPI AG in Metabolites
- Vol. 12 (4) , 277
Open AccessPredictive Modeling of Alzheimer’s and Parkinson’s Disease Using Metabolomic and Lipidomic Profiles from Cerebrospinal Fluid
In recent years, metabolomics has been used as a powerful tool to better understand the physiology of neurodegenerative diseases and identify potential biomarkers for progression. We used targeted and untargeted aqueous, and lipidomic profiles of the metabolome from human cerebrospinal fluid to build multivariate predictive models distinguishing patients with Alzheimer’s disease (AD), Parkinson’s disease (PD), and healthy age-matched controls. We emphasize several statistical challenges associated with metabolomic studies where the number of measured metabolites far exceeds sample size. We found strong separation in the metabolome between PD and controls, as well as between PD and AD, with weaker separation between AD and controls. Consistent with existing literature, we found alanine, kynurenine, tryptophan, and serine to be associated with PD classification against controls, while alanine, creatine, and long chain ceramides were associated with AD classification against controls. We conducted a univariate pathway analysis of untargeted and targeted metabolite profiles and find that vitamin E and urea cycle metabolism pathways are associated with PD, while the aspartate/asparagine and c21-steroid hormone biosynthesis pathways are associated with AD. We also found that the amount of metabolite missingness varied by phenotype, highlighting the importance of examining missing data in future metabolomic studies.
- Open Access
- 10 November 2021
- Published by Ubiquity Press, Ltd. in Tremor and Other Hyperkinetic Movements
- Vol. 11 (1)
Role of Directional Configuration in Deep Brain Stimulation for Essential Tremor: A Single Center Experience
Traditionally, the standard of care for medication refractory essential tremor has been to utilize omnidirectional deep brain stimulation of the ventral intermediate nucleus. The advent of directional stimulation allows for spatial restriction of the stimulation on selected targets without involving the neighboring structures, thereby limiting off-target side effects and improving clinical utility. We performed a retrospective review of patients between February 2017 and September 2019 who had received ventral intermediate nucleus deep brain stimulation that allowed for directional programming (specifically Abbott/St. Jude). Initial and final major programming sessions post-operatively (approximately 30- and 90-days post-surgery) were examined to determine frequency and reason for use of directional programming. A total of 33 total patients were identified. A little over half were males (58%, N = 19), with an average age of 68 years old (SD 9.3) at the time of surgery, and a disease duration of almost 30 years (27.2, SD 19) with a wide range from 2–62 years. After initial programming, over 50% (17 of 33) of patients were using directional configurations. This increased to 85% (28 of 33) at the 90-day programming. Reasons for conversion to directional configuration included avoidance of side effects (specifically, muscle contractions (9/33), paresthesia (5/33), dysarthria (1/33) and gait ataxia (1/33)) or improved tremor control (12/33). Our single-center experience suggests that in the large majority of cases, directional leads were utilized and offered advantages in tremor control or side effect avoidance.
- 10 November 2021
- Published by Ubiquity Press, Ltd. in Tremor and Other Hyperkinetic Movements
- Vol. 11 (1)
Open AccessRole of Directional Configuration in Deep Brain Stimulation for Essential Tremor: A Single Center Experience
Traditionally, the standard of care for medication refractory essential tremor has been to utilize omnidirectional deep brain stimulation of the ventral intermediate nucleus. The advent of directional stimulation allows for spatial restriction of the stimulation on selected targets without involving the neighboring structures, thereby limiting off-target side effects and improving clinical utility. We performed a retrospective review of patients between February 2017 and September 2019 who had received ventral intermediate nucleus deep brain stimulation that allowed for directional programming (specifically Abbott/St. Jude). Initial and final major programming sessions post-operatively (approximately 30- and 90-days post-surgery) were examined to determine frequency and reason for use of directional programming. A total of 33 total patients were identified. A little over half were males (58%, N = 19), with an average age of 68 years old (SD 9.3) at the time of surgery, and a disease duration of almost 30 years (27.2, SD 19) with a wide range from 2–62 years. After initial programming, over 50% (17 of 33) of patients were using directional configurations. This increased to 85% (28 of 33) at the 90-day programming. Reasons for conversion to directional configuration included avoidance of side effects (specifically, muscle contractions (9/33), paresthesia (5/33), dysarthria (1/33) and gait ataxia (1/33)) or improved tremor control (12/33). Our single-center experience suggests that in the large majority of cases, directional leads were utilized and offered advantages in tremor control or side effect avoidance.